|Telmisartan||Hypertension||Tablets||20, 40 and 80 mg|
|Tolcapone||Parkinson's||Film-coated tablets||100 mg|
|Trazodone||Depression||XR tablets||75 and 150 mg|
|Triadenor®||Useful for the management of depressive disorders||Nov 2014|
|UMP + Folic Acid + B12||Useful for the treatment of spinal syndromes, neuralgias and polyneuropathies||Jul 2018|
|Valproate||Epilepsy||Oral solution||60 mg/ml and 300 mg/ml|
|Valsartan||Hypertension||Film-coated tablets||40, 80, 160 and 320 mg|
|Vivifast®||Useful in the management of several types of cognitive disorders||Nov 2015|
|Viviflux®||Indicated for stroke primary and secondary prevention and for cerebrovascular disorders||Sep 2011|
|Vivimind®||Intended to protect memory and cognitive functions in MCI patients||Nov 2010|
|Zolmitriptan||Migraine||Orodispersable tablets||2.5 and 5 mg|
|Zolpidem||Insomnia||Film-coated tablets||10 mg|
|Zonisamide||Epilepsy||Hard capsules||25, 50 and 100 mg|
[*] Differentiated product
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.